Your Messages Inbox
Your Article Summary
See Latest ArticlesDouble-digit increase in sales, operating profit and Core EPS
Roche, 07/24/09
In the first half of 2009 the Roche Group continued the strong performance of recent years. Group sales grew 10% in local currencies to 24.0 billion Swiss francs. The Pharmaceuticals Division's sales increased 11% in local currencies to 19.1 billion Swiss francs — this is twice the global market growth rate. Demand for the oncology drugs Avastin, Herceptin, MabThera/Rituxan, Xeloda and Tarceva continued to increase strongly, with dynamic growth seen in a number of emerging markets. In addition, Tamiflu and Pegasys in virology and Lucentis in ophthalmology contributed significantly to growth.
Today in Financial Reports...keeping you current
Receive free subspecialty "5-minute updates" via email
Medtronic Board Approves Third Quarter Cash Dividend for Fiscal Year 2010
Medtronic, 12/04/09
Taro Provides Preliminary Third Quarter and Year-to-Date 2009 Financial Results
Taro Pharmaceuticals USA, 12/03/09
IMS Predicts 4% to 6% Global Pharma Market Growth Next Year
U.S. Pharmacist, 12/02/09
Article Search
Sponsor